Home › Trevena Announces Successful End-Of-Phase 2 Meeting With FDA And Outlines Phase 3 Program For Oliceridine
 

Keywords :   


Trevena Announces Successful End-Of-Phase 2 Meeting With FDA And Outlines Phase 3 Program For Oliceridine

2016-05-03 02:52:15| drugdiscoveryonline News Articles

Trevena, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, recently announced the successful completion of the End-of-Phase 2 Meeting process with the United States Food and Drug Administration (FDA)

Tags: for program meeting successful

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
03.07Greece starts six-day working week for some industries
03.07ThaMa-Vet unveils fixed dosage swine syringes
03.07Hurricane Beryl Graphics
03.07Farm Progress America, July 3, 2024
03.07Farm Progress America, July 3, 2024
03.07Digital video subscriptions to reach 3.5 billion by 2028
03.07Hurricane Beryl Forecast Discussion Number 19
03.07Hurricane Beryl Wind Speed Probabilities Number 19
More »